William A. Haseltine, Contributor

Even prior to the COVID-19 outbreak, more than 400 people died in US hospitals each day due to poor hospital performance, according to a 2019 report. Many of these deaths could be prevented.

Without more accurate tests, we must ensure repeated testing of those identified as having been exposed for traces of SARS-CoV-2 and continued long term follow-up screening of all convalescents.

Making low cost Covid-19 tests available to all is not just an achievable and necessary target, but the right thing to do.

Anti-coronavirus drugs and vaccines could have stopped Covid-19 dead in its tracks well before it spread beyond Wuhan, but those drugs and vaccines still lie many months in our future.

It would take a concerted effort, but in the United States we have the infrastructure and manpower it takes to conduct rapid antibody tests quickly, cheaply, and at a massive scale.

Is there a Covid-19 treatment that can treat critically ill, hospitalized patients, on the one hand, and protect healthcare workers on the other? Passive immune therapy has the potential to do both—immediately, and with major improvements over time.

The laws of nature are not dictated by market forces. If we wish to survive this pandemic and the next, we must leverage emergency funding mechanisms to accelerate the effort now and continue it even when Covid-19 is well behind us.

When a friend asked me if this was the big one two weeks ago, I was not sure. Today I can answer: Yes.

Known locally as Inshuti Mu Buzima, Partners In Health is implementing an innovative rural healthcare model that has developed some of the best health institutions in all of Rwanda and even the African continent.

What do the disappointing results from the controlled clinical trial on the use of hydroxy chloroquine as a treatment for Covid-19 mean for our ability to control the pandemic?